2.85mm

Lulzbot Bio (Announced)

Sold Out Free

Available Stock:
Loading...

This product has been discontinued. Contact us if you would like assistance choosing an alternative.

Lulzbot Bio - Bioprinting 3D Printer

FluidForm’s novel platform of Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D printing enables fabrication of soft, biological scaffolds for applications in tissue engineering and regenerative medicine.

Technical Specs

Material Safety Data Sheet | Technical Data Sheet

Print Technology: Fluid Deposition Fabrication
Print Head: Syringe Pump Extruder
Maximum Print Area: 160mm x 160mm x 89mm1 (6.30in x 6.30in x 3.5in1 )
Minimum Layer Resolution: 50 µm2
Minimum Positive Feature Size: 80 µm3
Calculated XYZ Positional Resolution: 10, 10, 5 µm
Recommended Operating Temperature: From 5°C to 40°C (41°F to 104°F)
Operating Footprint: 45.7cm x 40.6cm (18in x 16in)
Connectivity: USB Serial and SD Card
Print Surface: Heated Borosilicate Glass
Maximum Print Surface Temperature: Up to 120°C (248°F)
Print Surface Heat Up Time: 23°C to 60°C (73°F to 140°F) in 97 seconds
Interface: Glove-Friendly 4.5” Touch-Screen

Electrical and Software

Power Requirements: 100VAC-240VAC, 50Hz-60Hz, 3.2A max
Output: 24VDC
Power Supply: IEC cord, C13 to region-specific connector
Operating System Compatibility: GNU/Linux, Mac, Windows
Recommended Software: Cura LulzBot Edition (Latest Version)
Firmware: Marlin
Supported File Types: .stl, .obj, .g, .gcode, .x3d, .3mf

3D Bioprinting: Revolutionizing Key Industries.

3D biofabrication technology is revolutionizing applications across a wide spectrum of industries, including pharmaceuticals, regenerative medicine, drug screening, food and other animal products, cell-based biosensors, and testing of cosmetics and other health care goods. Within the next decade, major pharmaceutical companies will be able to replace some animal testing and non-physiological 2D cell culture systems with clinically-relevant 3D bioprinted human tissues.

“Combining proven expertise in professional 3D printers and hardware with 3D biofabrication technology is going to be an absolute game-changer, the market for 3D bioprinters and 3D bioprinted tissues is estimated to grow to $1.9 billion by 2028.” - Aleph Objects CEO and President Grant Flaharty.